Welcome to Bio-Link
Bio-Link is a life sciences business development company which facilitates partnerships based on technology review, project management, business development and deal negotiation. Bio-Link has offices in Melbourne and Sydney.
Our clients include Australian biotech companies and medical research institutes as well as organisations located outside Australia. Our portfolio extends across small molecule and peptide drug candidates, genetic and protein biomarkers and other leading technologies.
Bio-Link adds value to the commercialisation process through critical assessment of patents, packaging of pre-clinical and clinical data, technology marketing and identification and engagement with potential collaborators, licensees, or investors.
Our team has experience in therapeutics and diagnostics and has been involved in a number of commercial transactions in the USA, Europe and Australia.
Please explore this website to gain more information about our team, our clients and our portfolio.
|
|
|
|
19th April 2012 - Deal Announcement
Bio-Link has facilitated a commercial arrangement between the Lions Eye Institute (LEI), Perth and Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) around the Akimba model of diabetic retinopathy developed by Prof. Elizabeth Rackoczy and her colleagues at LEI.
16th February 2012 - Dairy Australia
Bio-Link has been engaged by Dairy Australia to commercialise LAP001, a natural bioactive peptide for the prevention and treatment of obesity, and Kappacin, a milk-derived protein for the treatment of oral microbial diseases.
25th November 2011 - CuroNZ NRP2945 for Multiple Sclerosis
Bio-Link has been engaged by CuroNZ Limited to secure commercial partners for its neuralregenerative peptide NRP2945 for the treatment of multiple sclerosis and other CNS diseases.
12th October 2011 - Deal Announcement
Bio-Link has facilitated a global licence, supply and distribution agreement for the first rationally designed clathrin inhibitors.The deal between Freie Universitaet Berlin, Children's Medical Research Institute, University of Newcastle and Ascent Scientific (United Kingdom) covers inclusion of these compounds in Ascent’s catalogue for research uses. Click here for the press release.
25th July 2011 - Deal Announcement
Bio-Link has facilitated a commercial partnership between Capital Biosciences Inc. (USA) and the Children's Medical Research Institute for a new testing service based on the analysis of telomere maintenance in biological samples. Click here for the press release.